William Allan Corp Purchases 9,275 Shares of Danaher Corporation $DHR

Key Points

• William Allan Corp purchased 9,275 Danaher shares worth approximately $2.06 million, making DHR about 1.1% of its portfolio. Institutional investors collectively own 79.05% of the company.
• Analysts remain generally bullish, with Danaher receiving a consensus “Moderate Buy” rating and an average price target of $235.41, though some firms recently reduced their targets.
• Danaher’s latest quarter exceeded expectations, with EPS of $1.94 and revenue of $6.26 billion, while its NVIDIA partnership and planned AI-powered autonomous laboratory offer potential longer-term growth catalysts.

William Allan Corp purchased a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 9,275 shares of the conglomerate's stock, valued at approximately $2,055,000. Danaher accounts for about 1.1% of William Allan Corp's investment portfolio, making the stock its 27th largest holding.

A number of other institutional investors have also modified their holdings of the stock. Main Street Group LTD acquired a new position in shares of Danaher in the 1st quarter valued at about $25,000. N.E.W. Advisory Services LLC acquired a new stake in Danaher during the second quarter worth about $25,000. Marquette Asset Management LLC grew its holdings in Danaher by 192.1% during the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate's stock worth $25,000 after acquiring an additional 73 shares during the period. Evolution Wealth Management Inc. grew its holdings in Danaher by 208.0% during the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate's stock worth $29,000 after acquiring an additional 104 shares during the period. Finally, Field & Main Bank purchased a new position in Danaher during the second quarter valued at approximately $29,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Barclays boosted their price target on Danaher from $230.00 to $255.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. Stifel Nicolaus dropped their price objective on shares of Danaher from $260.00 to $220.00 and set a "buy" rating on the stock in a research note on Wednesday, July 22nd. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a report on Saturday, October 10th. UBS Group initiated coverage on shares of Danaher in a report on Wednesday, September 9th. They set a "buy" rating and a $250.00 target price for the company. Finally, Wells Fargo & Company decreased their target price on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Danaher presently has an average rating of "Moderate Buy" and a consensus price target of $235.41.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Danaher Stock Performance

NYSE DHR opened at $224.65 on Thursday. The stock has a market capitalization of $157.93 billion, a price-to-earnings ratio of 39.90, a PEG ratio of 2.80 and a beta of 0.76. The stock has a 50-day moving average of $212.92 and a 200 day moving average of $195.39. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period last year, the company earned $0.77 earnings per share. Danaher's quarterly revenue was up 5.5% compared to the same quarter last year. Sell-side analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio (DPR) is 28.42%.

About Danaher

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.